Nevro or Nuvectra

[anonymous]

Because they know they are a one trick pony and the long term stats are going to be dismal. They are already the #1 x planted device and we haven't even gotten to the 2 year mark.

Total bullshit. Where is evidence to support this claim?

 

[anonymous]

Total bullshit. Where is evidence to support this claim?

There isn't any. He made it up.

 

[anonymous]

They are already the #1 x planted device and we haven't even gotten to the 2 year mark.

Alternative facts?

 

[anonymous]

What is the sales culture like at Nevro? It seems like morale is low despite having a pretty great product.

Stress is good for you and people who pursue happiness are less happy over time. Nevro CEO presented data supporting these claims our GSM. I'll let you deduce what the sales culture at Nevro is like.

 

[anonymous]

Doctor who does 40-50 stim implants a month, from all manufacturers (Med, BS, StJ, Nevro, Nuvectra) has ex-planted "15-20 of 50 implanted" of Nevro. Has done 25 Algovita implants with 0 ex-plants.

They have a big problem coming down the pike. Live recording at the link: http://www.wsw.com/webcast/cc/nvtr/ (go to the 103 minute for the discussion around ex-plants, and about 98 min mark for the downside of Nevro).

 

[anonymous]

Stress is good for you and people who pursue happiness are less happy over time. Nevro CEO presented data supporting these claims our GSM. I'll let you deduce what the sales culture at Nevro is like.

I know three that have left Nevro because they were lied to about territory splits. There is a lot of others with paper on the streets

 

[anonymous]

You mean he only had to explant all those Algovita leads right? No IPG's, just leads LOL. Face it, you need to employ Sherlock Holmes just to find an Algovita system. Who really puts this dinosaur in besides MR in Chicago???

 

[anonymous]

I know three that have left Nevro because they were lied to about territory splits. There is a lot of others with paper on the streets

I have yet to see evidence that Nevro leadership has any respect for their sales people or desire to produce anything meaningful with the amazing tech we have. It's all about the current/next quarter. Kind of makes the claims that Nevro's not for sale sound like bullshit.

 

[anonymous]

You mean he only had to explant all those Algovita leads right? No IPG's, just leads LOL. Face it, you need to employ Sherlock Holmes just to find an Algovita system. Who really puts this dinosaur in besides MR in Chicago???

Oklahoma puts in a lot of Alovita's. they've taken a significant amount of my market share

 

[anonymous]

Doctor who does 40-50 stim implants a month, from all manufacturers (Med, BS, StJ, Nevro, Nuvectra) has ex-planted "15-20 of 50 implanted" of Nevro. Has done 25 Algovita implants with 0 ex-plants.

They have a big problem coming down the pike. Live recording at the link: http://www.wsw.com/webcast/cc/nvtr/ (go to the 103 minute for the discussion around ex-plants, and about 98 min mark for the downside of Nevro).

my favorite part of this "panel" is how both docs talk about high success rates no matter whose products they are using. Drees should cough up a study directly comparing rates or stop with the competition is 65%, we're at 80-95% nonsense.

 

[anonymous]

Mid West grabbing larger share also.

 

[anonymous]

Because they know they are a one trick pony and the long term stats are going to be dismal. They are already the #1 x planted device and we haven't even gotten to the 2 year mark.

I don't know about explants, but any Nevro rep that tells you that they don't have a problem with perm success rates is lying. We had a breakout at the GSM dedicated to the issue. According to Nevro, it's the reps fault for allowing docs to pick the wrong patients. Apparently, it is possible to increase sales by turning down trials. Unfortunately no guidance was provided for this brilliant strategy.

 

[anonymous]

I don't know about explants, but any Nevro rep that tells you that they don't have a problem with perm success rates is lying. We had a breakout at the GSM dedicated to the issue. According to Nevro, it's the reps fault for allowing docs to pick the wrong patients. Apparently, it is possible to increase sales by turning down trials. Unfortunately no guidance was provided for this brilliant strategy.

ELEPHANT IN THE ROOM; Every SCS company has a problem with long term implanted success rates. Every successful trial is not a long-term successful implant. Nevro has demonstrated superiority, but 20%+ of patients in the Nevro arm of the Senza RCT at 2 years were at less than 50% pain relief. Compare that to 50%+ failure rate (Kumar, North, Boston arm of Senza, SUNBURST) for predicate devices. I have yet to see any prospective, independly audited/controlled studies showing better than a 50% failure rate for non-HF10 therapies.

The brilliant strategy is simple: support every case and do your job to promote good patient selection. Manage expectations.

 

[anonymous]

ELEPHANT IN THE ROOM; Every SCS company has a problem with long term implanted success rates. Every successful trial is not a long-term successful implant. Nevro has demonstrated superiority, but 20%+ of patients in the Nevro arm of the Senza RCT at 2 years were at less than 50% pain relief. Compare that to 50%+ failure rate (Kumar, North, Boston arm of Senza, SUNBURST) for predicate devices. I have yet to see any prospective, independly audited/controlled studies showing better than a 50% failure rate for non-HF10 therapies.

The brilliant strategy is simple: support every case and do your job to promote good patient selection. Manage expectations.

Is it painful to have Marketing's arm so far up your ass, Mr. Puppet?

 

[anonymous]

Is it painful to have Marketing's arm so far up your ass, Mr. Puppet?

Leaves a tingling sensation that I'd rather do without - much like paresthesia... really

 

[anonymous]

ELEPHANT IN THE ROOM; Every SCS company has a problem with long term implanted success rates. Every successful trial is not a long-term successful implant. Nevro has demonstrated superiority, but 20%+ of patients in the Nevro arm of the Senza RCT at 2 years were at less than 50% pain relief. Compare that to 50%+ failure rate (Kumar, North, Boston arm of Senza, SUNBURST) for predicate devices. I have yet to see any prospective, independly audited/controlled studies showing better than a 50% failure rate for non-HF10 therapies.

The brilliant strategy is simple: support every case and do your job to promote good patient selection. Manage expectations.

Yes the 20% is also the explant rate. That ipg is a pig with lipstick. Maybe even higher than 20% now. OUCH!

 

[anonymous]

Yes the 20% is also the explant rate. That ipg is a pig with lipstick. Maybe even higher than 20% now. OUCH!

Got any data to support that? Maybe a poster from NANS? Something?

Oh, you don't.

 

[anonymous]

Well, there might not be a paper from NANS, but this list of board tracks problems with med devices and the number of explants detailed by physicians and hospitals is alarming: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/results.cfm

Care to comment?

 

[anonymous]

Well, there might not be a paper from NANS, but this list of board tracks problems with med devices and the number of explants detailed by physicians and hospitals is alarming: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/results.cfm

Care to comment?

Nice link.

 

[anonymous]

Nice link.

I clicked through the last 20 of these maude events - all I see are infection related or procedural related events. Not one related to the device or its efficacy.

Nice try, Nuvectra troll.

Keep trying.